Skip to main content
Fig. 5 | Thrombosis Journal

Fig. 5

From: Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

Fig. 5

a Area under the plasma concentration–time curve from time 0–24 h (AUC); (b) maximum plasma concentration (Cmax) and (c) minimum plasma concentration measured 20–24 h after rivaroxaban administration (C_24h) versus age for rivaroxaban 10 mg dose equivalent; and (d) AUC, (e) Cmax and (f) C_24h versus age for rivaroxaban 20 mg dose equivalent, for children and adolescents between 6 months and 18 years of age, compared with the corresponding PBPK model predictions for children and adolescents, simulated via PBPK modelling and population PK modelling (box-whisker plot indicating the percentiles 5, 25, 50, 75 and 95). The grey shaded region shows the interval between the 5th and 95th percentiles of the population simulations with the PBPK model, the dashed shaded region shows an enlarged expected range due to uncertainties of some physiological parameters in children that may affect the absorption and clearance. The upper limit of this expanded range was calculated as 1.5 x 95th percentile and the lower limit was calculated as 0.5 x 5th percentile of the PBPK model estimate. PBPK, physiologically based pharmacokinetic; PK, pharmacokinetics

Back to article page